# US 12,006,295 B1 · 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,295 B1
- Document ID: US12006295B1
- Status: Granted
- Kind: B1
- Application number: 18/387,918
- Filed: 2023-11-08
- Granted: 2024-06-11
- Earliest claimed: 2023-11-08
- Assignees: King Faisal University
- Applicants: King Faisal University
- Inventors: Mai Mostafa Khalaf Ali; Hany Mohamed Abd El-Lateef Ahmed; Antar Ahmed Abdelhamid Ahmed
- Web page: https://patentgrep.com/patent/US12006295B1

## CPC

- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

## Claims

### Claim 1

A pharmaceutically acceptable composition comprising a therapeutically effective amount of an 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole compound having the formula I:
and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

A method of treating a gram positive bacteria in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1, wherein the gram positive bacteria is Staphylococcus aureus.

### Claim 3 (depends on 1)

A The method of treating one or more gram negative bacteria comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1, wherein the one or more gram negative bacteria are Pseudomonas aeruginosa, Escherichia coli, or a combination thereof.

### Claim 4 (depends on 1)

A method of treating a fungus in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1, wherein the fungus is Candida albicans.